Format

Send to

Choose Destination
Viruses. 2014 Jul 22;6(7):2858-79. doi: 10.3390/v6072858.

Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.

Author information

1
Department of Clinical Virology, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA. kirsten.white@gilead.com.
2
Department of Infectious Diseases, University Hospital, Hotel-Dieu, 1 Place Ricordeau, Nantes 44093, France. francois.raffi@wanadoo.fr.
3
Department of Clinical Virology, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA. michael.miller@gilead.com.

Abstract

The integrase (IN) strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), comprise the newest drug class approved for the treatment of HIV-1 infection, which joins the existing classes of reverse transcriptase, protease and binding/entry inhibitors. The efficacy of first-line regimens has attained remarkably high levels, reaching undetectable viral loads in 90% of patients by Week 48; however, there remain patients who require a change in regimen due to adverse events, virologic failure with emergent resistance or other issues of patient management. Large, randomized clinical trials conducted in antiretroviral treatment-naive individuals are required for drug approval in this population in the US, EU and other countries, with the primary endpoint for virologic success at Week 48. However, there are differences in the definition of virologic failure and the evaluation of drug resistance among the trials. This review focuses on the methodology and tabulation of resistance to INSTIs in phase 3 clinical trials of first-line regimens and discusses case studies of resistance.

PMID:
25054884
PMCID:
PMC4113796
DOI:
10.3390/v6072858
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center